
AVBP Stock Forecast & Price Target
AVBP Analyst Ratings
Bulls say
ArriVent BioPharma is viewed favorably because its lead asset firmonertinib still has meaningful upside in EGFR PACC NSCLC, supported by strong Phase 1b data of 68% confirmed ORR, 16.0-month PFS, and 53% CNS ORR, while the ongoing global Phase 3 ALPACCA study could enable accelerated or full approval if results are positive. Its second major value driver is the ADC pipeline, especially ARR-217, whose first-in-human data showed 38% confirmed ORR at the 6 mg/kg RP2D, about 7.1-7.2 months mPFS, and a favorable safety profile, with additional dose-optimization and combination data in 1H27 and 2H27 that could broaden the opportunity into earlier-line colorectal and other GI cancers. The balance sheet also supports the thesis, with $393.2M in cash and investments expected to fund operations to mid-2028, giving the company enough runway to absorb the FURVENT setback while advancing multiple catalysts.
Bears say
ArriVent BioPharma is facing a major setback as the registrational global Ph 3 FURVENT study of firmonertinib in 1L EGFR exon20ins NSCLC failed to meet its primary PFS endpoint by BICR, undermining confidence in the company’s lead asset. Although the 240mg arm showed numerically better results, including 11.0 vs. 9.5 months mPFS, 60% vs. 33% cORR by BICR, and 11.1 vs. 7.1 months INV-assessed mPFS, the key BICR miss and discordance in the chemo control arm leave the clinical interpretation uncertain. With the company still reviewing the full dataset and not planning a firmonertinib update until 1Q27, the near-term catalyst profile looks weak and the exon20ins opportunity remains excluded from the model.
This aggregate rating is based on analysts' research of ArriVent Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.
AVBP Analyst Forecast & Price Prediction
Start investing in AVBP
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About ArriVent Biopharma Inc (AVBP) Forecast
AVBP Analyst Forecast & Price Prediction
Start investing in AVBP
Order type
Buy in
Order amount
Est. shares
0 shares